Total Payments
$14,961
2024 Payments
$49.77
Companies
16
Transactions
152
Medicare Patients
589
Medicare Billing
$312,593
Payment Breakdown by Category
Consulting$6,975 (46.6%)
Food & Beverage$6,678 (44.6%)
Travel$1,201 (8.0%)
Education$107.67 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,975 | 2 | 46.6% |
| Food and Beverage | $6,678 | 140 | 44.6% |
| Travel and Lodging | $1,201 | 8 | 8.0% |
| Education | $107.67 | 2 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $7,603 | 17 | $0 (2023) |
| Novo Nordisk Inc | $2,187 | 47 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,544 | 33 | $0 (2023) |
| Olympus Corporation of the Americas | $1,307 | 11 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $504.73 | 5 | $0 (2023) |
| GlaxoSmithKline, LLC. | $340.22 | 8 | $0 (2020) |
| Insmed, Inc. | $242.77 | 3 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $241.40 | 3 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $209.92 | 2 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $202.74 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $49.77 | 2 | Merck Sharp & Dohme LLC ($27.22) |
| 2023 | $976.59 | 27 | Boehringer Ingelheim Pharmaceuticals, Inc. ($264.44) |
| 2022 | $7,971 | 35 | AstraZeneca Pharmaceuticals LP ($7,055) |
| 2021 | $1,294 | 21 | Novo Nordisk Inc ($770.86) |
| 2020 | $265.23 | 9 | AstraZeneca Pharmaceuticals LP ($129.45) |
| 2019 | $2,281 | 34 | Novo Nordisk Inc ($492.48) |
| 2018 | $905.67 | 10 | Boehringer Ingelheim Pharmaceuticals, Inc. ($613.58) |
| 2017 | $1,218 | 14 | Olympus Corporation of the Americas ($857.60) |
All Payment Transactions
152 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $27.22 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/19/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: Diabetes | ||||||
| 12/04/2023 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $106.32 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 10/24/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $22.60 | General |
| Category: Diabetes | ||||||
| 10/02/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $29.17 | General |
| Category: RESPIRATORY | ||||||
| 09/12/2023 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: Respiratory | ||||||
| 09/11/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: RESPIRATORY | ||||||
| 09/11/2023 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $22.99 | General |
| Category: Respiratory | ||||||
| 09/07/2023 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $124.58 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 08/29/2023 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 08/18/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: RESPIRATORY | ||||||
| 08/13/2023 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Immunology | ||||||
| 07/23/2023 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $26.04 | General |
| Category: Respiratory | ||||||
| 07/21/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: RESPIRATORY | ||||||
| 07/17/2023 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: Respiratory | ||||||
| 07/14/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $48.13 | General |
| 06/22/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: RESPIRATORY | ||||||
| 06/13/2023 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: Immunology | ||||||
| 06/10/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $111.05 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/19/2023 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Respiratory | ||||||
| 05/18/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: RESPIRATORY | ||||||
| 04/05/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: Diabetes | ||||||
| 03/21/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $27.48 | General |
| Category: RESPIRATORY | ||||||
| 03/17/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: Diabetes | ||||||
| 02/28/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 127 | 651 | $295,704 | $89,603 |
| 2022 | 6 | 142 | 978 | $370,550 | $113,290 |
| 2021 | 5 | 146 | 543 | $192,067 | $54,546 |
| 2020 | 6 | 174 | 506 | $194,562 | $55,153 |
Total Patients
589
Total Services
2,678
Medicare Billing
$312,593
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Office | 2023 | 45 | 548 | $244,408 | $76,428 | 31.3% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Office | 2023 | 21 | 24 | $12,648 | $3,963 | 31.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 14 | 22 | $19,498 | $3,959 | 20.3% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 14 | 14 | $6,244 | $1,937 | 31.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 25 | $6,120 | $1,806 | 29.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 14 | 18 | $6,786 | $1,510 | 22.3% |
| 99310 | Follow-up nursing facility visit per day, typically 35 minutes | Facility | 2022 | 40 | 711 | $277,290 | $87,301 | 31.5% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Facility | 2022 | 19 | 151 | $40,166 | $12,583 | 31.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 15 | 24 | $20,972 | $4,910 | 23.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 36 | 49 | $18,767 | $4,280 | 22.8% |
| 99306 | Initial nursing facility visit per day, typically 45 minutes | Facility | 2022 | 15 | 16 | $7,712 | $2,427 | 31.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 27 | $5,643 | $1,789 | 31.7% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2021 | 44 | 393 | $104,931 | $33,547 | 32.0% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 43 | 71 | $61,111 | $14,640 | 24.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 22 | 28 | $10,920 | $2,555 | 23.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 16 | 24 | $9,408 | $1,979 | 21.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 21 | 27 | $5,697 | $1,825 | 32.0% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2020 | 34 | 276 | $73,968 | $23,484 | 31.7% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 54 | 111 | $93,926 | $23,055 | 24.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 22 | 30 | $9,180 | $2,914 | 31.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 24 | 43 | $5,160 | $2,762 | 53.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 18 | 23 | $4,876 | $1,559 | 32.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 22 | 23 | $7,452 | $1,379 | 18.5% |
About Dr. Mediha Ibrahim, M.D
Dr. Mediha Ibrahim, M.D is a Critical Care Medicine healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2009. The National Provider Identifier (NPI) number assigned to this provider is 1962639849.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mediha Ibrahim, M.D has received a total of $14,961 in payments from pharmaceutical and medical device companies, with $49.77 received in 2024. These payments were reported across 152 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($6,975).
As a Medicare-enrolled provider, Ibrahim has provided services to 589 Medicare beneficiaries, totaling 2,678 services with total Medicare billing of $312,593. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease
- Location Brooklyn, NY
- Active Since 06/17/2009
- Last Updated 08/16/2019
- Taxonomy Code 207RC0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1962639849
Products in Payments
- TEZSPIRE (Biological) $7,076
- Ozempic (Drug) $1,459
- EVIS EXERA (Device) $857.60
- OFEV (Drug) $830.91
- ENTRESTO (Drug) $484.73
- Olympus EBUS Bronchoscopes (Device) $449.17
- NUCALA (Biological) $340.22
- Rybelsus (Drug) $327.56
- DUPIXENT (Biological) $241.40
- Tresiba (Drug) $229.56
- ELIQUIS (Drug) $209.92
- FASENRA (Biological) $167.13
- FASENRA (Drug) $126.88
- FARXIGA (Drug) $125.00
- Saxenda (Drug) $125.00
- LifeVest (Device) $124.58
- Kerendia (Drug) $109.54
- XARELTO (Drug) $107.88
- PURIFIED CORTROPHIN GEL (Drug) $106.32
- Arikayce (Drug) $99.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Brooklyn
Dr. Joshua Rosenberg, M.d, M.D
Critical Care Medicine — Payments: $893,165
Critical Care Medicine $893,165
Dr. Aaliya Burza, M.d, M.D
Critical Care Medicine — Payments: $54,441
Critical Care Medicine $54,441
Dr. Keerthana Keshava, M.b.b.s, M.B.B.S
Critical Care Medicine — Payments: $23,722
Critical Care Medicine $23,722
Dr. Yizhak Kupfer, Md, MD
Critical Care Medicine — Payments: $22,120
Critical Care Medicine $22,120
Igor Chernyavskiy, M.d, M.D
Critical Care Medicine — Payments: $7,598
Critical Care Medicine $7,598
Chetana Pendkar, M.b.b.s, M.B.B.S
Critical Care Medicine — Payments: $6,717
Critical Care Medicine $6,717